TScan Therapeutics Files 8-K

Ticker: TCRX · Form: 8-K · Filed: 2025-09-09T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, SEC Filing, Financials

TL;DR

TScan Therapeutics filed a routine 8-K, no major news.

AI Summary

TScan Therapeutics, Inc. filed an 8-K on September 9, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not disclose specific financial figures or material events beyond its routine reporting obligations.

Why It Matters

This 8-K filing indicates TScan Therapeutics is fulfilling its regular reporting requirements with the SEC, including the submission of financial statements and exhibits.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting financial statements and exhibits, not indicating any new material events or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by TScan Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.

On what date was this 8-K report filed?

The report was filed on September 9, 2025.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is TSCAN THERAPEUTICS, INC.

In which state was TScan Therapeutics, Inc. incorporated?

TScan Therapeutics, Inc. was incorporated in Delaware.

What is the business address and phone number of TScan Therapeutics, Inc.?

The business address is 830 Winter Street, Waltham, Massachusetts 02451, and the telephone number is (857) 399-9500.

From the Filing

0001193125-25-198768.txt : 20250909 0001193125-25-198768.hdr.sgml : 20250909 20250909070022 ACCESSION NUMBER: 0001193125-25-198768 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20250909 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250909 DATE AS OF CHANGE: 20250909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 251301631 BUSINESS ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d125738d8k.htm 8-K 8-K false 0001783328 0001783328 2025-09-09 2025-09-09     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2025     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 7.01 Regulation FD Disclosure. On September 9, 2025, TScan Therapeutics, Inc. (the “Company”) made available an updated corporate presentation (the “Presentation”) that it intends to use in potential meetings with investors, analysts, and other stakeholders. The Presentation reflects revisions to the Company’s anticipated development and operational milestones, including adjusted timelines for its solid tumor program, updates to the Company’s pipeline for both the hematologic malignancies and solid tumor programs, and updates on its target discovery initiatives in autoimmunity. The stockholders and investors

View on Read The Filing